Case Studies

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

Patients with an objective response to treatment had an enrichment of neoantigen-reactive T cells and these cells showed a phenotype that differed from non-responding patients, specifically displaying a late differentiated effector-like phenotype similar to viral-specific CD8 + T cells targeting cytomegalovirus (CMV) or Epstein-Barr virus (EBV), associated with cytotoxic T cells capable of controlling persistent viral infections (9).

Read More

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumor infiltrates

Patients with an objective response to atezolizumab treatment had an enrichment of neoantigen-reactive T cells and these cells showed a phenotype that differed from non-responding patients, specifically displaying a late differentiated effector-like phenotype similar to CMV-specific CTLs capable of controlling persistent viral infections. Results from this study suggest that detection and phenotypic profiling of neoantigen-specific T cells in the periphery might support patient selection for immune checkpoint inhibition strategies.

Read More

Top